AOA Dx

📍 Denver, United States🗓 Founded 2020👥 55 employees💰 Last funded Nov 2025
Biotechnology Research🌐 aoadx.com
Website LinkedIn
AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by lipids, metabolites and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GD™, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer.
10
Total investors
2
Early stage
8
Mid stage
0
Late stage
2020
Founded

Investors

10 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
10
Investor activity2021–2025 · investors recorded per year
20212202352024220251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in AOA Dx?
AOA Dx has 10 investors on record on gritt.io, including 2 early-stage backers, 8 mid-stage.
When did AOA Dx last raise funding?
The most recent investment in AOA Dx recorded on gritt.io was in November 2025.
When was AOA Dx founded?
AOA Dx was founded in 2020.
What industry is AOA Dx in?
AOA Dx operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AOA Dx based?
AOA Dx is headquartered in Denver, United States.